ArticleJournal of fungi (Basel, Switzerland)2025
Can We Have Guidelines or Just Guidance for Rare Fungal Infections?
Article in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unusual Sporotrichosis: A New Concept Proposal on the Unexpected Faces ofJournal of fungi (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this perspective, we discuss the limitations of medical guidelines as it relates to the management of uncommon invasive fungal infections (IFIs) or infrequent manifestations of more common IFIs. We emphasize the difficulties to define "gold standards" for diagnostics and treatment based on limited and low-quality evidence. We posit that such "guidelines" based on scarce data may be suboptimal and could be in some cases even harmful. Specifically, guidelines are often seen as rigid rules to follow which can prevent a critical examination of the nuanced management of individual patients with rare IFIs. We also emphasize that guidelines are often not updated frequently enough and therefore may not reflect the current treatment landscape. For all those reasons, we suggest that the term "guidance" may be more appropriate than "guidelines" for rare IFIs. Finally, we pose several questions regarding constructing future "Guidelines"/"Guidance for such entities".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.